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BACKGROUND: There are limited data on the management strategies, temporal trends and clinical outcomes of patients who 
present with non– ST- segment– elevation myocardial infarction and have a prior history of CABG.
METHODS AND RESULTS: We identified 287 658 patients with non– ST- segment– elevation myocardial infarction between 2010 
and 2017 in the United Kingdom Myocardial Infarction National Audit Project database. Clinical and outcome data were ana-
lyzed by dividing into 2 groups by prior history of coronary artery bypass grafting (CABG): group 1, no prior CABG (n=262 362); 
and group 2, prior CABG (n=25 296). Patients in group 2 were older, had higher GRACE (Global Registry of Acute Coronary 
Events) risk scores and burden of comorbid illnesses. More patients underwent coronary angiography (69% versus 63%) 
and revascularization (53% versus 40%) in group 1 compared with group 2. Adjusted odds of receiving inpatient coronary 
angiogram (odds ratio [OR], 0.91; 95% CI, 0.88– 0.95; P<0.001) and revascularization (OR, 0.73; 95% CI, 0.70– 0.76; P<0.001) 
were lower in group 2 compared with group 1. Following multivariable logistic regression analyses, the OR of in- hospital major 
adverse cardiovascular events (composite of inpatient death and reinfarction; OR, 0.97; 95% CI, 0.90– 1.04; P=0.44), all- cause 
mortality (OR, 0.96; 95% CI, 0.88– 1.04; P=0.31), reinfarction (OR, 1.02; 95% CI, 0.89– 1.17; P=0.78), and major bleeding (OR, 
1.01; 95% CI, 0.90– 1.11; P=0.98) were similar across groups. Lower adjusted risk of inpatient mortality (OR, 0.67; 95% CI, 
0.46– 0.98; P=0.04) but similar risk of bleeding (OR,1.07; CI, 0.79– 1.44; P=0.68) and reinfarction (OR, 1.13; 95% CI, 0.81– 1.57; 
P=0.47) were observed in group 2 patients who underwent percutaneous coronary intervention compared with those man-
aged medically.
CONCLUSIONS: In this national cohort, patients with non– ST- segment– elevation myocardial infarction with prior CABG had a 
higher risk profile, but similar risk- adjusted in- hospital adverse outcomes compared with patients without prior CABG. Patients 
with prior CABG who received percutaneous coronary intervention had lower in- hospital mortality compared with those who 
received medical management.
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Coronary artery bypass grafting (CABG) is a com-monly used revascularization strategy for the management of advanced coronary artery dis-
ease.1,2 Graft failure is not uncommon, with occlusive 
disease of saphenous vein grafts (SVGs) affecting ap-
proximately two- thirds of patients within 10  years of 
surgery.3– 5 Bypass grafting accentuates the develop-
ment of atherosclerosis, thrombosis, and calcification 
in native coronary arteries.6– 9 Consequently, occlusion 
of SVG and progression of native coronary artery dis-
ease are associated with the medium- and long- term 
risk of recurrent ischemic events, including myocardial 
infarction (MI).
Current European and American guidelines pro-
vide a class 1 recommendation for an early invasive 
approach in high- risk patients with non– ST segment 
elevation MI (NSTEMI) based on the results of 10 ran-
domized trials, which compared invasive versus med-
ical management.10– 13 However, many of these key 
trials14– 17 did not include patients with prior CABG or 
only recruited small numbers of such patients. Previous 
evidence derived from observational data has revealed 
that an invasive strategy is less likely to be adopted in 
patients with NSTEMI with prior CABG,17– 20 and when 
coronary angiography is undertaken, these patients are 
less likely to receive revascularization. Clinical outcome 
data in this cohort are inconsistent. For example, in a 
post hoc analysis of the ACUITY (Acute Catheterization 
and Urgent Intervention Triage Strategy) trial, adjusted 
30- day and 1- year risk of major adverse cardiovascular 
events (MACEs) was higher in patients with prior CABG 
who underwent revascularization compared with 
those who were treated conservatively.18 In contrast, in 
a Swedish registry of 10 837 patients with prior CABG, 
1- year adjusted mortality was 50% lower in those who 
received revascularization compared with those who 
received medical management.21 No randomized con-
trolled trial has exclusively examined the outcomes 
of this patient cohort in NSTEMI,22 although in a pilot 
trial of 60 patients, medically stabilized patients with 
NSTEMI with a prior history of CABG were randomly 
assigned to invasive or medical management. Similar 
clinical outcomes were reported in the 2 treatment 
strategies, although the sample size was inadequate 
to draw conclusions about the effectiveness of an in-
vasive strategy. Therefore, the optimal management 
strategy in patients with prior CABG who present with 
NSTEMI is not clearly defined. Hence, this study aimed 
CLINICAL PERSPECTIVE
What Is New?
• Patients with prior coronary artery bypass graft-
ing (CABG) are older, with greater comorbid 
burden and present with higher GRACE (Global 
Registry of Acute Coronary Events) score com-
pared with patients with no prior history of CABG.
• Once differences in baseline characteristics and 
presentation were adjusted for, we observed 
similar odds of inpatient mortality, major adverse 
cardiovascular events, reintervention, and major 
bleeding between the 2 groups.
• Sensitivity analysis of the prior CABG patients 
who received percutaneous coronary interven-
tion showed they had better- adjusted clinical 
outcomes for in- hospital all- cause mortality com-
pared with those who received medical manage-
ment, despite the observation that patients with 
prior CABG were less likely to receive invasive 
management.
What Are the Clinical Implications?
• Percutaneous coronary intervention was under-
used in patients with non– ST- segment– elevation 
myocardial infarction who had a prior history of 
CABG, though it was associated with mortality 
benefit compared with conservative management.
• These results may provide insight to clinicians 
around the utility of an invasive management ap-
proach in this high- risk and complex cohort of 
patients.
• Prospective, randomized, controlled clinical trials 
are now needed to test the validity of these obser-
vational results.
Nonstandard Abbreviations and Acronyms
ACUITY Acute Catheterization and 
Urgent Intervention Triage 
Strategy
GRACE Global Registry of Acute 
Coronary Events
LIPSIA- NSTEMI Leipzig Immediate Versus 
Early and Late Percutaneous 
Coronary Intervention Trial in 
NSTEMI
MACE major adverse cardiovascular 
event
MINAP Myocardial Infarction National 
Audit Project
OASIS- 5 Organization to Assess 
Strategies in Ischemic 
Syndromes– 5
RITA3 Randomized Intervention Trial 
of Unstable Angina 3
SVG saphenous vein graft
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to (1) investigate management strategies and clinical 
outcomes of patients presenting with NSTEMI with a 
history of prior CABG in contemporary clinical practice 
and (b) analyze the association of an invasive approach 
to in- hospital clinical outcomes using the data from the 




This analysis is based on the data derived from 
MINAP, a comprehensive, national clinical registry of 
patients hospitalized with type 1 MI in England and 
Wales.23,24 The MINAP data set consists of 130 vari-
ables and records information about patients with 
acute MI including baseline clinical characteristics, co-
morbid conditions, management strategies including 
invasive and conservative, pharmacotherapy, place 
of care, in- hospital clinical outcomes, and diagnosis 
on discharge. Data are submitted by hospital clinical 
and clerical staff, and pseudorandomized records are 
uploaded to the National Institute for Cardiovascular 
Outcomes Research central database. Two hundred 
six hospitals enter over 92 000 new cases to MINAP 
annually, and approximately 1.5 million patient records 
are currently present in this database. Institutional re-
search and ethical board approval were not required 
for this study, as all data were anonymized and rou-
tinely collected as part of the national audit. Because 
of the sensitive nature of the data collected for this 
study, requests to access the data set from qualified 
researchers trained in human subject confidential-
ity protocols may be sent to the National Institute for 
Cardiovascular Outcomes Research at nicor.help-
desk@nhs.net.
Study Design
This is a retrospective analysis of prospectively col-
lected data of patients admitted with a diagnosis of 
NSTEMI in England and Wales between January 1, 
2010, and December 31, 2017. The discharge diagno-
sis of NSTEMI was decided by treating clinicians ac-
cording to presenting complaints, clinical examination, 
and the results of in- hospital investigations in keep-
ing with the European Society of Cardiology guide-
lines.25 Patients with missing data for prior history of 
CABG, mortality, and any individual patient with sec-
ond or later admissions were excluded from analysis 
(Figure 1). This constituted a final cohort of 287 658 
patients with NSTEMI, which were then categorized 
into 2 groups according to history of CABG: group 1, 
patients with no prior history of CABG; and group 2, 
patients with prior CABG. Clinical outcomes of inter-
est were in- hospital all- cause mortality, reinfarction, 
major bleeding, and MACEs. MACE was defined as a 
composite end point of inpatient death or reinfarction. 
Major bleeding was defined as a composite of gastro-
intestinal, retroperitoneal, and intracranial hemorrhage. 
Patient risk assessment was performed using the TIMI 
(Thrombolysis in Myocardial Infarction) and GRACE 
(Global Registry of Acute Coronary Events) scoring 
systems.26– 28
Statistical Analysis
Descriptive statistical analyses were performed to 
compare differences in baseline demographics, clini-
cal characteristics, and crude adverse outcomes 
between the 2 cohorts. Continuous variables are pre-
sented as means and SDs and categorical variables by 
proportions. The chi- squared test and Student’s t test 
were used to assess statistical differences between 
the 2 groups, in categorical and continues variables, 
Figure 1. Consolidated Standards of Reporting Trials diagram to show to show all participant 
inclusion and exclusion.
CABG indicates coronary artery bypass grafting; MINAP, Myocardial Infarction National Audit Project; 
and NSTEMI, non– ST- segment– elevation myocardial infarction.
Total NSTEM patients present in MINAP data from 2010-2017, n = 369,435
Excluded patients with missing data for prior history of CABG (n= 23,360) & mortality (n=10,570)
Inclusion of data for patients first admission = 287,658 (47,847 excluded due to second or more 
later admission)
Data for final analysis = 287,658
1- CABG naïve patients, n = 262,362
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respectively. We undertook multiple imputations with 
chained equation techniques to impute data for all 
variables with missing data.29 We applied multivariable 
logistic regression analysis first on complete case anal-
ysis and then on imputed data sets to estimate the risk 
of adverse outcomes between groups. Estimates were 
combined using Rubin’s rules.30 Logistics regression 
models were fitted using maximum likelihood estima-
tion and were adjusted for those variables that con-
tributed significantly to adverse outcomes and had a 
P value <0.05 by using backward selection method. In 
multivariable analyses, we adjusted for age, sex, race, 
heart rate, blood pressure, body mass index, serum 
creatinine level, family history of coronary artery dis-
eases, ischemic ECG changes, left ventricular systolic 
dysfunction, prior percutaneous coronary intervention 
(PCI), comorbid conditions (history of diabetes mel-
litus, hypercholesterolemia, angina, cerebrovascular 
accident, peripheral vascular disease, hypertension, 
smoking, admission under cardiology, pharmaco-
therapy (prescription of unfractionated heparin, intra-
venous nitrate, furosemide, mineralocorticoid receptor 
antagonist, beta blockers, angiotensin- converting en-
zyme inhibitor/angiotensin receptor blockers, aspirin, 
P2Y12 inhibitor, statins), Killip class, cardiac arrest, car-
diogenic shock, pulmonary edema, and procedures 
and investigations including coronary angiogram and 
PCI undertaken during admission.
In a sensitivity analysis, we used propensity score 
matching with the imputed data, to estimate the aver-
age treatment effects. We matched the 2 groups on 
the same variables used in the multivariable statistical 
analyses. One- to- one nearest- neighbor matching with 
replacement was applied, followed by logistic regres-
sion analysis (the sole predictor being group member-
ship) to obtain the average treatment effects over the 
multiple imputed data sets. The coefficients were con-
verted to odds ratios to allow for comparisons with the 
main analysis.
All statistical analyses were performed with Stata 
14.2 (College Station, TX). All statistical analyses were 
2- tailed, and an alpha of 5% was used throughout.
RESULTS
Our study cohort consisted of 287 658 patients who 
were admitted in England and Wales from January 
2010 to December 2017 with a diagnosis of NSTEMI, 
of which 25 296 (9%) had a prior history of CABG. The 
process of patients’ inclusion and exclusion for this 
analysis is presented in Figure 1. The annual proportion 
of patients with prior CABG during the study period 
ranged from 8.36% (2010) to 9.56% (2016) (P<0.001) 
(Figure 2).
Differences in baseline clinical characteristics between 
the 2 groups are presented in Table 1. Patients with 
prior CABG were significantly older, less likely to be 
women and White, but more likely to present with acute 
heart failure symptoms. The proportion of patients 
with a high- risk GRACE score (>140) was significantly 
higher in patients with prior CABG compared with pa-
tients without prior CABG (88% versus 76%; P<0.001). 
Furthermore, patients with prior CABG had a higher 
prevalence of comorbid conditions such as diabetes 
mellitus, congestive heart failure, chronic renal failure, 
hypercholesterolemia, previous MI and PCI, angina, 
Figure 2. Proportion of prior CABG in total patients with NSTEMI during study period.
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cerebrovascular accident, peripheral vascular disease, 
hypertension, asthma/chronic obstructive pulmonary 
disease, and severe left ventricular systolic dysfunction. 
Pharmacotherapy, management strategies, and unad-
justed crude clinical outcomes for both cohorts are 
presented in Table 2. The proportion of patients who 
Table 1. Clinical Characteristics
Variables CABG Naïve (n=262 362) Prior CABG (n=25 296) P Value
Mean age, y (SD) 71 (14) 74 (10) <0.0001
Women, n/N (%) 98 641/262 362 (38) 5249/25 296 (21) <0.001
White, n/N (%) 221 796/240 353 (92) 20 955/23 342 (90) <0.001
Mean body mass index, n (SD) 28 (8) 28 (8) 0.16
Race
White (%) 221 796/240 353 (92%) 20 955/23 342 (90%) <0.001
Black (%) 2420/240 353 (1%) 168/23 342 (1%)
Asian (%) 12 921/240 353 (6%) 1882/23 342 (8%)
Mixed (%) 3216/240 353 (1%) 337/23 342 (1%)
Killip class
No heart failure, n/N (%) 131 283/169 808 (77) 11 727/16 398 (72) <0.001
Basal crepitations, n/N (%) 27 326/169 808 (16) 3468/16 398 (21) <0.001
Pulmonary edema, n/N (%) 10 215/169 808 (6) 1090/16 398 (7) 0.001
Cardiogenic shock, n/N (%) 984/169 808 (0.58) 113/16 398 (0.69) 0.08
GRACE score, n/N (%)
High- risk GRACE score >140 125 852/164 912 (76) 13 887/15 855 (88) <0.001
Intermediate- risk GRACE score 
109– 140
31 338/164 912 (19) 1673/15 855 (11) <0.001
Low- risk GRACE score <109 7722/164 912 (5) 295/15 855 (2) <0.001
Other clinical characteristics
ECG ST changes, n/N (%) 198 810/255 910 (78) 19 448/24 642 (79) <0.001
Previous smoker, n/N (%) 89 504/250 038 (36) 11 778/23 908 (49) <0.001
Current smoker, n/N (%) 57 514/250 038 (23) 2772/23 908 (12) <0.001
Chronic renal failure, n/N (%) 21 299/260 091 (9) 3712/24 772 (15) <0.001
Prior percutaneous coronary 
intervention, n/N (%)
30 157/261 618 (12) 7274/24 757 (29) <0.001
Diabetes mellitus, n/N (%) 62 559/260 248 (24) 10 412/25 048 (42) <0.001
Congestive heart failure, n/N (%) 18 330/260 050 (7) 3678/24 707 (15) <0.001
Hypercholesterolemia, n/N (%) 87 740/257 531 (34) 11 875/24 575 (48) <0.001
Previous MI, n/N (%) 62 226/201 068 (27) 16 242/24 857 (65) <0.001
Angina, n/N (%) 68 358/259 721 (28) 16 877/24 764 (68) <0.001
Cerebrovascular disease, n/N (%) 25 500/260 508 (10) 3476/24 814 (14) <0.001
Peripheral vascular disease, n/N (%) 12 589/259 581 (5) 2686/24 685 (11) <0.001
Hypertension, n/N (%) 141 155/260 496 (54) 15 943/24 981 (64) <0.001
Asthma/COPD, n/N (%) 45 571/260 574 (17) 4 496/24 833 0.02
Family history of CAD, n/N (%) 60 829/219 8550 (28) 5447/19 992 (27) 0.20
Admission under cardiologist, n/N 
(%)
127 559/251 037 (51) 11 939/24 257 (49) <0.001
Mean heart rate, bpm (SD) 82 (22) 79 (22) <0.001
Mean systolic blood pressure (SD) 141 (28) 140 (28) <0.001
Moderate LVSD (EF 35%– 45%), 
n/N (%)
36 027/206 989 (17) 4741/19 996 (24) <0.001
Severe LVSD (EF <35%), n/N (%) 14 820/206 989 (7) 2211/19 996 (11) <0.001
Cardiac arrest, n/N (%) 8574/256 647 (3) 986/24 806 (4) <0.001
CABG indicates coronary artery bypass grafting; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; EF, ejection fraction; GRACE, 
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received furosemide (42% versus 27%; P<0.001) was 
markedly higher in the prior CABG group, reflecting the 
greater proportion of patients with HF in this cohort. 
The proportion of patients who received an invasive 
coronary angiogram (63% versus 69%; P<0.001), PCI 
(39% versus 45%; P<0.001), and CABG (1% versus 
8%; P<0.001) were significantly lower in patients with 
a history of CABG.
Temporal Changes
In a temporal analysis to assess PCI during the study 
period, we observed an increase in PCI over time 
in group 1 (no prior CABG) (P for trend <0.001) and 
Group 2 (prior CABG) cohorts (P for trend <0.001) 
(Figure 3).
Clinical Outcomes in Patients Without 
Prior CABG Versus Patients With Prior 
CABG
The prevalence of in- hospital all- cause mortality (5.4% 
versus 5.1; P=0.08), major bleeding (1.58% versus 
1.7%; P=0.17), MACE (6% in each group; P=0.95) were 
similar in both cohorts, but reinfarction was higher in 
patients with prior CABG (1.1% versus 0.9%; P<0.001). 
After adjustment for differences in baseline clinical and 
treatment characteristics, odds of all- cause mortal-
ity (OR, 0.96; 95% CI, 0.88– 1.04; P=0.31), reinfarction 
(OR, 1.02; 95% CI, 0.89– 1.17; P=0.78), major bleeding 
(OR, 1.01; 95% CI, 0.90– 1.11; P=0.98), and inpatient 
MACE (OR, 0.97; 95% CI, 0.90– 1.04; P=0.44) were 
similar between the 2 groups (Table 3).
Table 2. Management Strategy and Crude Clinical Outcome
Variables CABG Naïve (n=262 362) Prior CABG (n=25 296) P Value
Pharmacotherapy, n/N (%)
Low- molecular- weight heparin 123 578/237 006 (52) 11 680/22 707 (51) 0.04
Fondaparinux 112 159/238 046 (47) 10 079/22 764 (44) <0.001
Warfarin 14 064/235 919 (6) 2626/22 606 (12) <0.001
Unfractionated heparin 33 108/235 250 (14) 2849/22 516 (13) <0.001
Glycoprotein 2b/3a inhibitor 7428/239 183 (3) 702/22 919 (3) 0.72
Intravenous nitrate (%) 29 994/235 872 (12.7) 3010/22 600 (13.3) 0.01
Furosemide 64 962/236 401 (27) 9483/22 730 (42) <0.001
Calcium channel blockers 43 849/236 045 (19) 6025/22 672 (27) <0.001
Intravenous beta blockers 2744/237 066 (1) 237/22 700 (1) 0.12
MRA 15 261/234 348 (7) 2699/22 455 (12) <0.001
Thiazide diuretics 11 300/235 555 (5) 1139/22 531 (5) 0.08
Aspirin 252 745/261 627 (97) 24 333/25 241 (96) 0.09
P2Y12 inhibitor 239 070/261 265 (91.5) 23 190/25 203 (92.1) 0.006
Statins 212 980/260 937 (82) 22 898/25 193 (91) <0.001
ACE inhibitors/ARB 211 428/261 158 (81) 21 176/25 200 (84) <0.001
Beta blockers 212 043/259 831 (82) 20 763/25 115 (83) <0.001
Management strategy, n/N (%)
Radionuclide study 5740/235 950 (2) 782/22 697 (3) <0.001
Exercise test 8953/239 578 (4) 742/23 033 (3) <0.001
Coronary angiogram 174 184/250 859 (69) 15 133/24 129 (63) <0.001
PCI 90 717/202 853 (45) 7503/19 248 (39) <0.001
CABG 16 350/202 853 (8) 269/19 248 (1.4) <0.001
Revascularization (CABG/PCI) 107 067/202 853 (53) 7772/19 248 (40) <0.001
Crude in- hospital clinical outcomes, n/N (%)
Death 14 075/262 362 (5.4) 1291/25 296 (5.1) 0.08
Cardiac mortality 10 899/262 362 (4.15) 1079/25 296 (4.27) 0.40
Reinfarction 2205/250 647 (0.9) 273/24 152 (1.1) <0.001
Major bleeding 4076/257 766 (1.58) 422/24 878 (1.7) 0.17
MACE* 15 749/262 362 (6) 1516/25 296 (6) 0.95
ACE indicates angiotensin- converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass grafting; MACE, major adverse 
cardiovascular event; MRA, mineralocorticoid receptor antagonist; and PCI, percutaneous coronary intervention.
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Analysis With Propensity Score Matching
In a propensity score matching analysis, the adjusted 
risk of mortality during index admission (OR, 0.98; 95% 
CI, 0.83– 1.14; P=0.82), in- hospital reinfarction (OR, 
1.27; 95% CI, 0.82– 1.72; P=0.24), in- hospital major 
bleeding (OR, 0.92; 95% CI, 0.69– 1.14; P=0.47), and 
in- patient MACE (OR, 1.03; 95% CI, 0.87– 1.20; P=0.67) 
were similar between the 2 groups (Table 4).
Figure 3. Temporal trends of PCI practice from 2010 to 2017.
P for trend PCI in patients with prior CABG < 0.001. P for trend for PCI in CABG- naïve patients < 0.001. 
CABG indicates coronary artery bypass grafting; and PCI, percutaneous coronary intervention.
Table 3. Risk of in- Hospital Adverse Outcomes Following Multivariate Adjustments
Clinical Outcomes
Adjusted OR† as Compared With 
Reference (CABG Naïve) P Value 95% CI
Complete case MV analyses
Death* (no. of observations=92 266) 1.003 0.97 0.86 to 1.17
Reinfarction* (n of observations=90 558) OR: 1.06 0.67 0.81 to 1.39
Major bleeding* (no. of observations=91 383) 1 1 0.84– 1.19
MACE‡ (no. of observations=92 266) 0.99 0.97 0.87– 1.14
Multivariate analyses on imputed data
Death (no. of observations=287 658) 0.96 0.31 0.88– 1.04
Reinfarction (no. of observations=287 658) 1.02 0.78 0.89– 1.17
Major bleeding (no. of observations=287 658) 1.01 0.98 0.90– 1.11
MACE‡ (no. of observations=287 658) 0.97 0.44 0.90– 1.04
CABG indicates coronary artery bypass grafting; MACE, major adverse cardiovascular event; MV; multivariable; OR, odds ratio; and PCI, percutaneous 
coronary intervention.
*Adjusted for age; sex; heart rate; blood pressure; family history of coronary heart diseases; ischemic ECG changes; left ventricular systolic dysfunction; 
history of diabetes mellitus, hypercholesterolemia, peripheral vascular disease, or hypertension; prescription of warfarin, intravenous nitrate, furosemide, 
aldosterone antagonist, beta blockers, angiotensin converting enzyme inhibitor/angiotensin receptor blockers, aspirin, P2Y12 inhibitor, or statins; Killip class; 
cardiac arrest; and coronary angiogram.
†Adjusted for age; sex; race; heart rate; blood pressure; serum creatinine level; family history of coronary heart diseases; ischemic ECG changes; left ventricular 
systolic dysfunction; PCI; history of diabetes mellitus, hypercholesterolemia, angina, cerebrovascular accident, peripheral vascular disease, hypertension, or 
smoking; admission under cardiology; warfarin; unfractionated heparin; intravenous nitrate; furosemide; calcium channel blockers; aldosterone antagonist; 
beta blockers; angiotensin- converting enzyme inhibitor/angiotensin receptor blocker; aspirin; P2Y12 inhibitor; statins; Killip class; cardiac arrest; coronary 
angiogram; and PCI on imputed data.
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Sensitivity Analysis
We undertook sensitivity analyses in patients with prior 
CABG to compare and contrast clinical characteris-
tics and adverse outcomes in those who received PCI 
compared with those who received medical manage-
ment only. Clinical characteristics of both cohorts are 
presented in Table S1, and pharmacotherapy, manage-
ment strategy, and crude in- hospital clinical outcomes 
are presented in Table S2. Patients who received medi-
cal management were older and had greater prevalence 
of chronic kidney disease and severe left ventricular 
systolic dysfunction compared with those who received 
PCI. Adjusted risks of in- hospital clinical outcomes are 
presented in Table 5. In patients with prior CABG, we 
observed lower odds of inpatient mortality (OR, 0.67, 
95% CI, 0.46– 0.98; P – 0.04) in those who under-
went PCI compared with those who received medi-
cal management alone (Table  5). However, the odds 
of in- hospital reinfarction, major bleeding, and MACE 
were not significantly different. In multivariate analyses, 
a history of prior CABG in patients with NSTEMI was 
independently associated with lower odds of inpatient 
coronary angiogram (OR, 0.91, 95% CI, 0.88– 0.95; 
P<0.001) and revascularization (PCI/CABG) (OR, 0.73; 
95% CI, 0.70– 0.76; P<0.001) (Tables S3 through S4).
Information about missing data is presented in 
Table  S5. Our study findings are summarized in 
Figure 4.
DISCUSSION
This large national study examines demographic and 
baseline clinical characteristics, pharmacotherapy, 
management strategies, and adverse clinical out-
comes in patients with a history of CABG presenting 
with NSTEMI. Our study demonstrates that patients 
with prior CABG are older, with greater comorbid bur-
den and present with higher GRACE score compared 
with patients with no prior history of CABG. Once 
differences in baseline characteristics and presenta-
tion were adjusted for, we observed similar odds of 
inpatient mortality, MACE, reintervention, and major 
Table 4. Propensity Score– Matched Analysis With Average Treatment Effects on Imputed Data
Outcome Group Coefficient* (95% CI) OR* (95% CI) P Value
In- hospital death (n=287 658) Group 1: CABG naïve Reference
Group 2: prior CABG −0.0009289 (−0.0090477 to 0.00719) 0.98 (0.83– 1.14) 0.82
In- hospital reinfarction (n=287 658) Group 1: CABG naïve Reference
Group 2: prior CABG 0.0023837 (−0.0016293 to 0.0063968) 1.27 (0.82– 1.72) 0.24
In- hospital Major bleeding (n=287 658) Group 1: CABG naïve Reference
Group 2: prior CABG −0.0013085 (−0.0048546 to 
0.0022376)
0.92 (0.69– 1.14) 0.47
In- hospital MACE† (n=287 658) Group 1: CABG naïve Reference
Group 2: prior CABG 0.001969 (−0.0070927 to 0.0110307) 1.03 (0.87– 1.20) 0.67
CABG indicates coronary artery bypass grafting; MACE, major adverse cardiovascular event; and OR, odds ratio.
*Adjusted for age; sex; race; heart rate; blood pressure; serum creatinine level; family history of coronary heart diseases; ischemic ECG changes; left 
ventricular systolic dysfunction; history of heart failure, prior percutaneous coronary intervention, diabetes mellitus, hypercholesterolemia, angina, myocardial 
infarction, cerebrovascular accident, peripheral vascular disease, hypertension, smoking, or asthma/chronic obstructive pulmonary disease; admission under 
cardiology; prescription of low- molecular- weight heparin, warfarin, unfractionated heparin, glycoprotein IIb/IIIa inhibitor, intravenous nitrate, furosemide, calcium 
channel blockers, aldosterone antagonist, fondaparinux, beta blockers, angiotensin- converting enzyme inhibitor/angiotensin receptor blocker, aspirin, P2Y12 
inhibitor, or statins; Killip class; cardiac arrest; coronary angiogram; or PCI on imputed data.
†MACE is defined as composite end point of inpatient death and reinfarction.
Table 5. Adjusted In- Hospital Clinical Outcomes in Patients With Prior CABG Who Received PCI Versus MEDICAL 
Management* (Medical Management is REFERENCE GROUP)
Clinical Outcomes
Adjusted OR* as Compared With 
Reference (CABG Naïve) P Value 95% CI
Death (no. of observations=25 027) 0.67 0.04 0.46– 0.98
Reinfarction (no. of observations=25 027) 1.13 0.47 0.81– 1.57
Major bleeding (no. of observations=25 027) 1.07 0.68 0.79– 1.44
MACE† (no. of observations=25 027) 0.94 0.63 0.73– 1.21
CABG indicates coronary artery bypass grafting; MACE, major adverse cardiovascular event; OR, odds ratio; and PCI, percutaneous coronary intervention.
*Adjusted for age, race, heart rate, blood pressure, serum creatinine level, left ventricle systolic dysfunction, history of diabetes mellitus or cerebrovascular 
accident, admission under cardiology, warfarin, unfractionated heparin, glycoprotein IIb/IIIa inhibitor, intravenous nitrate, furosemide, calcium channel blockers, 
aldosterone antagonist, beta blockers, angiotensin- converting enzyme inhibitor/angiotensin receptor blocker, aspirin, P2Y12 inhibitor, statins, Killip class, 
cardiac arrest, and coronary angiogram on imputed data.
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bleeding between the 2 groups. However, sensitivity 
analysis of the patients with prior CABG who received 
PCI showed they had better- adjusted clinical outcomes 
for in- hospital all- cause mortality compared with those 
who received medical management, despite the ob-
servation that patients with prior CABG were less likely 
to receive invasive management.
The American College of Cardiology/American 
Heart Association and European Society of Cardiology 
guidelines recommend an early invasive strategy in 
addition to medical therapy in patients who present 
with NSTEMI and have a high risk of adverse clinical 
outcomes.11,25 Patients with prior CABG are consid-
ered a high- risk group, and therefore, an early invasive 
approach is preferred in this group. However, patients 
with prior CABG have actually been excluded from 
many of the pivotal clinical trials like RITA3 (Randomized 
Intervention Trial of Unstable Angina 3) and Value of 
First Day Angiography/Angioplasty In Evolving Non- ST 
segment Elevation Myocardial Infarction: An Open 
Multicenter Randomized Trial,31– 35 which assess re-
vascularization against medical management. In other 
studies, too, only small numbers of patients with prior 
CABG were present in acute coronary syndrome (ACS) 
trials (LIPSIA- NSTEMI [Leipzig Immediate Versus Early 
and Late Percutaneous Coronary Intervention Trial 
in NSTEMI]: 41/600, Italian elderly ACS; After Eighty 
study: 76/457; OASIS- 5 [Fifth Organization to Assess 
Strategies in Ischemic Syndromes]: 1643/20 078).10,36– 40  
Apart from a recently published pilot randomized 
controlled trial, in which Lee et al22 described 24 months’ 
outcome data of 60 patients with prior CABG (invasive 
group, n=31; medical group, n=29), no major clinical 
trials specifically examined clinical outcomes of inva-
sive versus medical approach in patients with prior 
CABG who presented with NSTEMI.. During 2 years 
of follow- up (median, 744  days; interquartile range, 
570– 853), the composite outcome for efficacy (all- 
cause mortality, rehospitalization for refractory isch-
emia/angina, MI, hospitalization for HF) occurred in 13 
(42%) patients in the invasive group and 13 (45%) in 
the medical group (HR, 0.85; 95% CI, 0.39– 1.83). Five 
patients died in the invasive group and 3 in the medical 
management group. Because of the small sample size, 
it is not possible to provide recommendations about 
treatment strategies on the basis of this study. Thus, 
given the exclusion or underrepresentation of patients 
with prior CABG in pivotal NSTEMI clinical trials, cur-
rent guidelines are not genuinely based upon good 
evidence compared with patients with NSTEMI who 
have never had CABG. Our current analysis helps to 
address this evidence gap through data analysis of a 
large real- world national registry.
In the present study, patients with prior CABG were 
less likely to receive invasive coronary angiography, 
even once differences in baseline characteristics were 
adjusted for. There are many potential explanations for 
this observation. For example, patients with prior CABG 
often have a greater burden of comorbid illnesses and 
have more complex and extensive disease in native 
Figure 4. Clinical features and outcomes of patients with NSTEMI with prior CABG compared 
with CABG naïve.
CABG indicates coronary artery bypass grafting; DM, diabetes mellitus; GRACE, Global Registry of Acute 
Coronary Events; LVSD, left ventricular systolic dysfunction; MACE, major adverse cardiovascular event; 
NSTEMI, non– ST- segment– elevation myocardial infarction; PCI, percutaneous coronary intervention; and 
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coronary arteries and bypass grafts, which may make 
such patients less attractive for selective invasive 
management.41 Our findings are similar to those re-
ported by the Can Rapid Risk Stratification of Unstable 
Angina Patients Suppress Adverse Outcomes With 
EarlyImplementation Quality Improvement Initiative, 
which demonstrated that higher- risk patients are less 
likely to receive invasive management despite a greater 
possible benefit from a more aggressive therapeutic 
approach.42 Because of more widespread availability 
of computed tomography coronary angiography in re-
cent years, it is possible that some of the patients with 
prior CABG underwent a computed tomography cor-
onary angiogram instead of invasive coronary angiog-
raphy, and were subsequently not offered an invasive 
approach because of unfavorable anatomy or patent 
grafts.
In our study, revascularization, which was mainly in 
the form of PCI, was also less likely to be performed 
in patients with prior CABG. This corresponds to the 
previous observation that they were less likely to un-
dergo invasive angiography and is likely to reflect con-
cerns by clinicians about procedural risks relating to 
advanced age, higher comorbidity, well- documented 
higher complication rates, and a lack of clear evidence 
of benefit in the CABG cohort.9,43 There might be a 
group of the patients who received assessment of 
viable myocardium with noninvasive imaging, or who 
underwent a computed tomography coronary an-
giogram/invasive coronary angiogram, and were not 
considered for revascularization because of either the 
absence of viability or flow- limiting lesions suitable for 
PCI. Despite using modern drug- eluting stent platforms 
and adjuncts like embolic protection devices, long- 
term outcomes of SVG PCI are suboptimal. The prob-
ability of no- reflow and periprocedural MI are found to 
be higher in PCI to SVG compared with native- vessel 
PCI in many studies.9,44 Moreover, bypass grafts ac-
centuate the progression of atherosclerosis and calci-
fication in native coronary vessels with up to two- fifths 
of bypassed native arteries developing chronic total 
occlusions after 1 year of surgery.7 Certainly, PCI to ei-
ther SVGs or in native coronary arteries in patients with 
prior CABG are technically more challenging compared 
with procedures undertaken in patients without a prior 
history of CABG. These observations may add to the 
uncertainties about performing complex PCI when the 
procedural risk may be perceived to be higher than 
any potential benefits associated with an invasive ap-
proach, with medical management opted for.
In multivariate and propensity score matching anal-
yses, we found the odds of in- hospital mortality, major 
bleeding, reinfarction, and MACE were similar between 
patients with and without prior CABG. These findings 
are consistent with previously published data by Kim et 
al41 and Teixeira et al.1 In an analysis of 47 557 patients 
with NSTEMI (prior CABG, 8790), Kim and colleagues 
reported no significant differences in inpatient mortality 
(OR, 0.99; 95% CI, 0.87– 1.11) and bleeding (OR, 1; 95% 
CI, 0.92– 1.11). Similarly, Teixeira et al reported similar 
adjusted odds in- hospital mortality (9.5% versus 5.9%; 
P=0.2), or mortality at 1 year (9.8% versus 9.1; P=0.84), 
major adverse cardiac and cerebrovascular events at 
1 year (22 versus 17%; P=0.37) and almost 50% of 
patients underwent an invasive coronary angiogram 
during hospital admission. Unlike the present analysis, 
neither of these studies analyzed the effect of PCI on 
adverse clinical outcomes in patients with prior CABG.
Our analysis reports lower adjusted odds of in- 
hospital mortality in those patients with prior CABG who 
underwent PCI compared with those who managed 
conservatively without any additional risk of major bleed-
ing or reinfarction. However, patients with prior CABG 
who received PCI had a more favorable risk profile, and 
it might therefore be possible that some unmeasured 
confounders may have contributed to worse outcomes 
in the medically managed cohort. Furthermore, there 
might be a subset of patients with prior CABG who 
were older with a heavy burden of comorbid illnesses, 
and clinicians considered them not suitable for PCI. 
Nevertheless, this finding might be important from a 
clinical perspective, as PCI was underused in patients 
with NSTEMI who had a prior history of CABG in al-
most all of the previously published data and in present 
study, though it was associated with a mortality benefit 
compared with conservative management.41 These re-
sults may provide insight to clinicians around the utility 
of an invasive management approach in this high- risk 
and complex cohort of patients. Prospective, random-
ized controlled clinical trials are now needed to test the 
validity of these observational results.
Strengths and Limitations
This large national- level study is the first to provide 
a broad overview of real- world practice of manage-
ment strategies, temporal changes, and adverse clini-
cal outcomes of patients with a history of prior CABG 
and presenting with NSTEMI ACS. The MINAP data 
set comprises an almost complete record of all pa-
tients with NSTEMI admitted in the United Kingdom 
representing the largest real- world experience of this 
cohort of patients, containing high- risk patients with 
multiple comorbid illnesses that are often not included 
or underrepresented in clinical trials. The large sample 
size of this national study gives us sufficient statisti-
cal power to detect differences in adverse clinical out-
comes between the 2 cohorts of interest.
Despite having several strengths, certain limitations 
should be considered while interpreting our study 
observations. A key inherent limitation of the current 
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of prospectively collected data of a national registry 
and therefore was subject to all the limitations of ob-
servational studies. Second, although the MINAP data 
set included many important clinical and demographic 
variables of interest, much valuable additional infor-
mation like procedural details, operator experience, 
details about culprit vessels, infarct size, information 
about imaging investigations like computed tomog-
raphy coronary angiography and cardiac magnetic 
resonance, and lesion characteristics are not rou-
tinely collected. Third, MINAP records only in- hospital 
clinical outcomes, and it is possible that long- term 
follow- up data may reveal differences in clinical out-
comes between PCI and medically managed patients 
with prior CABG. Fourth, time- of- death data are not 
available in MINAP, and there is a possibility that some 
patients died during first few hours of admission with-
out getting assessment for a PCI, leading to an immor-
tal time bias that may account for the more favorable 
outcomes for those patients managed with PCI. Fifth, 
MINAP does not record information about whether PCI 
was undertaken in the native vessel or in vein grafts in 
patients with prior CABG. Our previous work around 
this theme, derived from the British Cardiovascular 
Intervention Society data set, suggests that outcomes 
are similar once differences in baseline characteristics 
are adjusted for.45 Finally, it is not clear from the MINAP 
data set whether the NSTEMI event was attributable to 
a ruptured plaque in either the bypass graft or native 
coronary artery, which may impact on management 
strategy and clinical outcomes differently.
CONCLUSIONS
Our study demonstrates that ≈1 in 11 patients who pre-
sent with NSTEMI ACS have a history of prior CABG. 
The odds of receiving an invasive coronary angiogram 
and revascularization remained low in the patients with 
prior CABG even after adjustment of baseline differ-
ences. Once differences in baseline characteristics 
were adjusted for, we report no significant differences 
in in- hospital MACE, reinfarction, mortality, and major 
bleeding between patients with prior CABG and pa-
tients without prior CABG who presented with NSTEMI 
ACS. Our analysis suggests lower odds of in- hospital 
mortality in patients with prior CABG who were man-
aged with PCI compared with those managed medi-
cally, without increased odds of major bleeding. This 
may suggest that an invasive approach may be associ-
ated with better outcomes in patients with prior CABG, 
although adequately powered randomized controlled 
clinical trials are needed to confirm these findings.
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Mean age in years (SD) 0 77 (70 -82) 73 (66 – 79) <0.001 










Mean BMI  (SD) 16,862 28 (5) 29 (12) 0.0001 
Killip class 




















GRACE score  







Intermediate risk GRACE 













Other clinical characteristics  































































































Mean heart rate, bpm (SD) 1,458 80 (22) 75 (20) <0.001 
Mean systolic blood 
pressure (SD) 
3,919 139 (28) 141 (26) <0.001 




















 Excluded those patients who received redo CABG and where data for PCI was missing 
 
CABG; Coronary artery bypass grafting, PCI; Percutaneous coronary intervention, MI; Myocardial 
infarction, BMI; Body mass index, GRACE: Global Registry of Acute Coronary Events, ECG; 
Electrocardiograph, CCF; Congestive cardiac failure, COPD; Chronic obstructive pulmonary disease, CAD; 
Coronary artery disease, IQR; Interquartile range, LVSD; left ventricular systolic dysfunction, EF; ejection 








Table S2. In-hospital management strategy & crude clinical outcomes in Prior CABG 




























































































Management strategy  















Crude in-hospital clinical outcomes 






























CABG; Coronary artery bypass grafting, IV; Intravenous, MRA; Mineralocorticoid receptor antagonist, 
ACE; angiotensin converting enzyme inhibitor, ARB; angiotensin receptor blockers, MACE; Major adverse 
cardiovascular events 
 










Table S3. Odds of receiving in-patient coronary angiogram in prior CABG patients in 
Multivariate analysis (reference: CABG naïve) (number of observations = 287,658). 
 
 




Prior CABG 0.91 <0.001 0.88 0.95 
Age 0.92 <0.001 0.92 0.95 
Female 0.63 <0.001 0.61 0.64 
Heart rate 0.992 <0.001 0.991 0.993 
BMI 1.016 <0.001 1.011 1.021 
Blood pressure 1.006 <0.001 1.005 1.007 
Creatinine level 
(mmol/l) 
0.997 <0.001 0.996 0.998 
Family history of CAD 1.48 <0.001 1.43 1.53 
Caucasians 1.28 <0.001 1.22 1.34 
ECG changes 0.91 <0.001 0.89 0.94 
Severe LVSD 0.81 <0.001 0.80 0.81 
Heart failure 0.71 <0.001 0.68 0.74 
Prior PCI 1.58 <0.001 1.52 1.64 
DM 0.88 <0.001 0.86 0.90 
Hypercholesterolaemia  1.37 <0.001 1.33 1.40 
Angina 0.87 <0.001 0.84 0.88 
Prior MI 0.69 <0.001 0.67 0.71 
Prior CVA 0.61 <0.001 0.59 0.63 
PVD 0.90 <0.001 0.86 0.94 
Hypertension 1.04 0.003 1.01 1.06 
Smoking 0.99 0.38 0.98 1.01 
Asthma/COPD 0.89 <0.001 0.87 0.91 
Admission under 
cardiology 
0.58 <0.001 0.57 0.59 
LMWH 1.09 <0.001 1.06 1.12 
Warfarin 0.99 0.86 0.94 1.05 
Unfractionated heparin 4.37 <0.001 4.18 4.58 
Glycoprotein 2b/3a 
antagonist 
2.35 <0.001 2.12 2.60 
IV nitrate  1.37 <0.001 1.31 1.43 
Furosemide 0.61 <0.001 0.59 0.63 
Calcium channel 
blockers 
1.03 0.06 0.99 1.05 
MRA 0.91 <0.001 0.87 0.96 
Fondaparinux 1.21 <0.001 1.18 1.24 








Exercise test 0.98 0.67 0.92 1.05 
Reinfarction 0.90 0.07 0.81 1.01 
Major bleeding 0.60 <0.001 0.56 0.65 
Betablockers 1.28 <0.001 1.24 1.32 
ACEI/ARB 1.59 <0.001 1.55 1.64 
Aspirin 1.64 <0.001 1.53 1.75 
P2Y12 inhibitor 1.99 <0.001 1.92 2.08 
Statins 0.89 <0.001 0.86 0.92 
Killip class 0.73 <0.001 0.71 0.75 
Cardiac arrest  0.45 <0.001 0.42 0.48 
Cardiogenic shock 4.09 <0.001 3.3 5.1 
Pulmonary oedema 1.33 <0.001 1.23 1.44 
 
CABG; Coronary artery bypass grafting, PCI; Percutaneous coronary intervention, MI; Myocardial 
infarction, BMI; Body mass index, GRACE: Global Registry of Acute Coronary Events, ECG; 
Electrocardiograph, CCF; Congestive cardiac failure, COPD; Chronic obstructive pulmonary disease, CAD; 
Coronary artery disease, LVSD; left ventricular systolic dysfunction, EF; ejection fraction, IV; Intravenous, 
MRA; Mineralocorticoid receptor antagonist, ACE; angiotensin converting enzyme inhibitor, ARB; 









Table S4. Odds of receiving in-patient revascularization (PCI/CABG) in prior CABG 
patients in Multivariate analysis (reference: CABG naïve) (number of observations = 
287,658). 
 




Prior CABG 0.73 <0.001 0.70 0.76 
Age 0.971 <0.001 0.971 0.972 
Female 0.60 <0.001 0.59 0.62 
Heart rate 0.992 <0.001 0.991  0.993 
BMI 1.02 <0.001 1.01 1.03 
Blood pressure 1.004 <0.001 1.003 1.005 
Creatinine level 
(mmol/l) 
0.998 <0.001 0.997 0.999 
Family history of CAD 1.30 <0.001 1.26 1.33 
Caucasians 1.17 <0.001 1.13 1.21 
ECG changes 1.06 <0.001 1.03 1.08 
Severe LVSD 0.94 <0.001 0.93 0.95 
Heart failure 0.77 <0.001 0.73 0.81 
Prior PCI 1.33 <0.001 1.28 1.37 
DM 0.99 0.54 0.97 1.01 
Hypercholesterolaemia  1.36 <0.001 1.33 1.39 
Angina 0.94 <0.001 0.92 0.96 
Prior MI 0.71 <0.001 0.69 0.73 
Prior CVA 0.71 <0.001 0.69 0.74 
PVD 1.02 0.38 0.98 1.03 
Hypertension 0.99 0.38 0.97 1.01 
Smoking 1.07 <0.001 1.06 1.09 
Asthma/COPD 0.94 <0.001 0.91 0.96 
Admission under 
cardiology 
0.66 <0.001 0.64 0.67 
LMWH 1.007 0.53 0.98 1.03 
Warfarin 0.78  0.73 0.82 
Unfractionated heparin 2.64 <0.001 2.57 2.72 
Glycoprotein 2b/3a 
antagonist 
2.40 <0.001 2.25 2.56 
IV nitrate  1.24 <0.001 1.20 1.29 
Furosemide 0.67 <0.001 0.64 0.69 
Calcium channel 
blockers 
0.94 <0.001 0.91 0.96 
MRA 0.86 <0.001 0.81 0.89 
Fondaparinux 1.02 0.08 0.99 1.04 








Exercise test 1.09 <0.001 1.03 1.14 
Reinfarction 1.09 0.13 0.97 1.21 
Major bleeding 0.98 0.58 0.91 1.05 
Betablockers 1.24 <0.001 1.20 1.28 
ACEI/ARB 1.37 <0.001 1.34 1.42 
Aspirin 1.64 <0.001 1.54 1.75 
P2Y12 inhibitor 1.98 <0.001 1.90 2.07 
Statins 1.06 <0.001 1.03 1.09 
Killip class 0.75 <0.001 0.73 0.78 
Cardiac arrest  0.67 <0.001 0.63 0.71 
Cardiogenic shock 3.87 <0.001 3.26 4.60 
Pulmonary oedema 1.41 <0.001 1.29 1.53 
 
CABG; Coronary artery bypass grafting, PCI; Percutaneous coronary intervention, MI; Myocardial 
infarction, BMI; Body mass index, GRACE: Global Registry of Acute Coronary Events, ECG; 
Electrocardiograph, CCF; Congestive cardiac failure, COPD; Chronic obstructive pulmonary disease, CAD; 
Coronary artery disease, LVSD; left ventricular systolic dysfunction, EF; ejection fraction, IV; Intravenous, 
MRA; Mineralocorticoid receptor antagonist, ACE; angiotensin converting enzyme inhibitor, ARB; 











Table S5. Information about Missing data. 
Variables Missing data 
Age (years) 0 
Women  0 
Caucasians  23,963 
BMI median  254,976 
No Heart failure  101,452 
Basal crepitations 101,452 
Pulmonary oedema  101,452 
Cardiogenic shock  101,452 
High risk GRACE score >140  106,891 
Intermediate risk GRACE score 109-140  106,891 
Low risk GRACE score <109  106,891 
ECG ST changes  7,106 
Previous smoker  13,712 
Current smoker  13,712 
Chronic renal failure  2,795 
Prior percutaneous coronary intervention  1,283 
Diabetes  2,362 
CCF  2,901 
Hypercholesterolemia  5,552 
Previous MI  1,733 
Angina  3,173 
Cerebrovascular disease  2,336 
Peripheral vascular disease  3,392 
Hypertension  1,731 
Asthma / COPD  2,251 
Family history of CAD  47,816 
Admission under Cardiologist  12,634 
Heart rate, bpm, median  20,255 
Systolic blood pressure 56,759 
Moderate LVSD (EF 35-45%) 60,673 
Severe LVSD (EF <35%) 60,673 
Cardiac arrest  6,205 
Low molecular weight heparin  27,945 
Fondaparinux 26,848 
Warfarin  29,133 
Unfractionated heparin 29,892 
Glycoprotein 2b/3a inhibitor  25,556 
IV Nitrate 29,186 
Furosemide  28,527 
Calcium channel blockers  28,941 
IV beta blockers  27,892 
MRA  30,855 
Thiazide diuretics  29,572 








P2Y12 inhibitor   1,190 
Statins   1,528 
ACE inhibitors/ARB   1,300 
Beta-Blockers   2,712 
Management strategy  
Radionuclide Study  29,011 
Exercise test 24,847 
Coronary angiogram  12,670 
Percutaneous coronary intervention  65,557 
CABG  65,557 
Revascularization (CABG/PCI) 65,557 
Crude in-hospital clinical outcomes 
Death  0 
Cardiac mortality  0 
Reinfarction  12,859 
Major bleeding  5,014 
MACE  0 
 
CABG; Coronary artery bypass grafting, PCI; Percutaneous coronary intervention, MI; Myocardial 
infarction, BMI; Body mass index, GRACE: Global Registry of Acute Coronary Events, ECG; 
Electrocardiograph, CCF; Congestive cardiac failure, COPD; Chronic obstructive pulmonary disease, CAD; 
Coronary artery disease, LVSD; left ventricular systolic dysfunction, EF; ejection fraction, IV; Intravenous, 
MRA; Mineralocorticoid receptor antagonist, ACE; angiotensin converting enzyme inhibitor, ARB; 
angiotensin receptor blockers, MACE; Major adverse cardiovascular events 
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